Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Just been doing a bit more reading up and as yet we have not heard about the Evidence Generation Plan which is supposed to be set up by GDR in conjunction with NICE to gather the evidence required, i remember at the time that a timescale was given , anyone remember as i have forgotten and cant find it ?.
Stockpick, in answer to your question, i have no idea . We have been told and seen that they will be world class products but as to why no sales yet is a conundrum to me and many others. We know AIHL is available to the NHS and elsewhere if they want it or can find the funding in their budgets. As Starrs has said because we dont have an unconditional recommendation yet so funding is not a must for trusts so it may be everywhere else is working on the same theory which i find hard to fathom, is it to do with the company , again dont know but what is plain to see the market wont move on this until sales commence, knowing when that will be is the prize.
LTH, with anything solid foundations are a must , we have that in bucket loads now , a litle more patience is now required to build the walls with sales, topping out with the roof will be very rewarding with a takeover , when??? who knows but it is coming.
Its a bit off a double edged sword, we need more sales to get the answers to the conditions set by NICE but then who will buy it without full NICE approval . We all know how slow the politics around funding go in the UK and yes. most of us have no real knowledge on how the medical proffession works so it would be good to hear from the company on how they plan to overcome the situation ??????.
LOL,Starrs, we both know NICE have given the go ahead to sell AIHL ANYWHERE , its just that as of yet no one has bought any , yes it may be because we dont have FULL approval but it can be bought, why hav nt we sold any yet ???? dont know.
The Genedrive MT-RNR1 ID Kit can be used while further evidence is generated as an option for detecting the genetic variant m.1555A>G to guide antibiotic (aminoglycoside) use and prevent hearing loss in newborns who are being considered for treatment with aminoglycosides.
1.2Healthcare professionals should tell parents about the possible implications of positive test results for their baby and their family at an appropriate time, and give support and information.
As far as I know NICE have not set a timescale on when they want the data or how much yet but it is clear this has to be rolled out wider to obtain the information to get a full recommendation and as I can't see the NHS or NICE funding it GDR may have to partially fund the cost of tests and machines to get that so that could be a way of getting funding from DEVOTE if a good enough case is put forward. We have also seen the share price jump up 20-30 percent on nothing so who knows what will happen this month, I don't for sure.